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Background. Paraoxonase 1 (PON1) enzymatic activity has been consistently predictive of cardiovascular disease, while the
genotypes at the four functional polymorphisms at PON1 have not. The goal of this study was to identify additional variation
at the PON gene cluster that improved prediction of PON1 activity and determine if these variants predict carotid artery disease
(CAAD). Methods. We considered 1,328 males in a CAAD cohort. 51 tagging single-nucleotide polymorphisms (tag SNPs) across
the PON cluster were evaluated to determine their eﬀects on PON1 activity and CAAD status. Results. Six SNPs (four in PON1 and
one each in PON2/3) predicted PON1 arylesterase (AREase) activity, in addition to the four previously known functional SNPs.
In total, the 10 SNPs explained 30.1% of AREase activity, 5% of which was attributable to the six identiﬁed predictive SNPs. We
replicate rs854567 prediction of 2.3% of AREase variance, the eﬀects of rs3917510, and a PON3 haplotype that includes rs2375005.
While AREase activity strongly predicted CAAD, none of the 10 SNPs predicting AREase predicted CAAD. Conclusions. This study
identiﬁes new genetic variants that predict additional PON1 AREase activity. Identiﬁcation of SNPs associated with PON1 activity
is required when evaluating the many phenotypes associated with genetic variation near PON1.
1.Introduction
Paraoxonase 1 (PON1) is a liver-produced glycoprotein en-
zyme bound to the surface of high-density lipopro-
tein (HDL) whose activity is consistently correlated with
atherosclerotic vascular disease and end-organ damage [1–
3]. PON1 is at least partially responsible for the inhibitory
eﬀects of HDL on low-density lipoprotein (LDL) peroxida-
tion [4–6] and also has been demonstrated to hydrolyze oxi-
dized lipid or lipid hydroperoxides in LDL [7]. Accordingly,
Watson et al. reported that inactivation of PON1 reduced
the ability of HDL to inhibit both the oxidation of LDL
and the interaction between macrophages and endothelium
[6], both likely key factors in the inﬂammatory changes
underlyingatherogenesis.IthasalsobeenshownthatPON1-
deﬁcient mice cannot neutralize the oxidized LDL lipids and
have an increased susceptibility to organophosphate toxicity
and coronary heart disease (CHD) [8, 9]. Finally, PON1
activity appears to play a role in maintaining the endothelial-
atheroprotective eﬀects of HDL [10].
There are four currently established functional common
PON1single-nucleotidepolymorphisms(SNPs)amongstthe
nearly 200 SNPs in the gene [11]: two missense muta-
tions(PON1Q192R[rs662]andPON1M55L[rs854560])andtwo
that alter promoter activity (PON1−108C/T[rs705379] and
PON1−162A/G[rs705381]). PON1−108C/T has the largest eﬀect,
altering expression likely due to modiﬁcation of an Sp1
binding site [12]. Rare functional variants have also been
identiﬁed [13].
While PON1 activity is predictive of vascular disease,
studies investigating the role of PON1 SNPs in vascular2 Journal of Lipids
disease have been contradictory [14–18]. A recent meta-
analysis of 88 case-control studies by Wang et al. found
that PON1Q192 was correlated with CHD [19]. However,
removal of smaller studies from the meta-analysis resulted
in none of the functional PON1 SNPs having signiﬁcant
association with CHD, thereby replicating the results of past
meta-analyses[20–22].Similarly,ourownpastinvestigations
have found that while PON1 enzyme levels are predictive
of carotid artery disease (CAAD), the genotypes at the four
common functional SNPs fail to predict CAAD status [2, 3].
However, studies of CAAD or ischemic strokes are generally
more positive for associations with the PON1 functional
SNPs[18,23–26]thanthoseforCHD.Itshouldbenotedthat
these studies generally have small sample size and several of
such studies reported negative results [27, 28].
PON1 has broad substrate speciﬁcity and is protective
against exposure to toxic organophosphorus insecticides
[29]. For biological purposes, PON1 activity is generally
measured with regard to the rate of hydrolysis of paraoxon,
diazoxon, and phenylacetate (arylesterase activity) [30, 31].
These are termed POase, DZOase, and AREase activities,
respectively. AREase enzymatic activity is unaﬀected by the
functional PON1Q192R polymorphism, thus making it the
best reﬂection of the levels of PON1 protein [32].
PON1 activity has also been linked to a number of
other health-related phenotypes in addition to vascular
diseaseanddiabetes[33].Forexample,PON1alsoinﬂuences
the metabolism of a variety of drugs, including statins,
in addition to its aforementioned properties of reducing
oxidizedLDLandbreakingdownpesticides[34].PON1Q192R
is a reported determinant of clopidogrel eﬃcacy [35],
although this result has not been replicated [36]a n d
remains controversial. PON1 has also been associated with
diverse diseases [37]. The PON1L55M polymorphism has
been repeatedly associated with Parkinson’s disease [38–40],
includingameta-analysis[41],butnullresultshavealsobeen
reported [42]. Recent meta-analyses reported the association
ofPON1codingSNPsandbreastcancer[43,44].BothPON1
activity and genotypes have been associated with age-related
macular degeneration [45–51]. PON1 activity is reportedly
lower in subjects with systemic lupus erythematosus (SLE)
[48, 52–54]. Finally, diabetes is associated with both reduced
PON1 activity and PON1 genotypes [55].
PON1 is one of three paraoxonase gene family members,
located in a gene cluster on chromosome 7q21.3-22.1. All of
the paraoxonases have antioxidant activity [56]. PON1 and
PON3 share similar functions in association with HDL as
described previously; however, PON3 has lower expression
levels [57]. In contrast, PON2 is ubiquitously expressed
in human cells [58], particularly in endothelial and aortic
smooth muscle cells [59]. PON2 polymorphisms have also
been associated with CHD [58, 60]. In addition, all three
PON gene products have been reported to hydrolyze the
quorum sensing factor of Pseudomonas aeruginosa N-3-
oxododecanoyl homoserine lactone (3OC12-HSL)[61], with
PON1 and 2 enzymes speciﬁcally being shown in animal
knock-out studies to be protective against p. aeruginosa
infection [62, 63].
Carlson et al. previously performed a tagSNP analysis
of the PON1, 2, and 3 gene cluster for association with
AREase activity and CAAD status in an overlapping, but
much smaller, cohort (n = 500 versus 1328) [27]. That
study found evidence that additional functional SNPs likely
exist in PON1, but that the majority of the genetic eﬀect on
AREase variation was explained by the four functional SNPs
previously described. They did not ﬁnd evidence for PON2
or PON3 SNPs predicting additional AREase activity.
However, the investigation by Carlson et al. still left a
large portion of the variation in PON1 activity unexplained.
Thus,thegoalsofthisstudyaretofollowupontheseprevious
results and utilize an enlarged cohort and denser tagSNP
genotyping toattempttoidentify novel commonSNPsin the
PON gene cluster that associate with PON1 activity and/or
predict CAAD.
2. Methods
2.1. Sample. The study population for this analysis con-
sisted of 1,328 samples from the previously described
Carotid Lesion Epidemiology And Risk (CLEAR) study
[2, 3, 64]. Only Caucasian males were analyzed due to
underrepresentation of female and minority samples in this
primarily Seattle-Veterans-based cohort. Current smoking
status and reported ancestry were obtained by self-report.
Ancestry was conﬁrmed using STRUCTURE with three
ancestral groups [65]. CAAD status was determined via
ultrasound of the internal carotid arteries, with cases deﬁned
as having >50% stenosis in either artery or a relevant
procedure on their carotid arteries in their medical history.
Controls had <15% stenosis in both arteries. 88 subjects
had intermediate stenosis (15–49%) and were not included
for prediction of CAAD, though they were included for
prediction of PON1 enzyme activity.
2.2. Genotyping and PON1 Phenotypes. The four
known functional PON1 SNPs, PON1Q192R, PON1M55L,
PON1−108C/T,a n dPON1−162A/G and two SNPs identiﬁed as
potentially predictive by Carlson et al. but not represented
on the CVD chip, PON1−909 (rs854572) and rs3917510 [27],
weregenotypedusingpreviouslydescribedmethods[12,66].
An additional 86 SNPs in PON1, PON2, and PON3 cluster
were genotyped using the Illumina HumanCVD BeadChip
(http://www.illumina.com/products/humancvd whole gen-
ome genotyping kits.ilmn). Duplicate genotyping for 34
individuals showed 99.7% consistency in calls. The PON
cluster genotypes were ﬁltered with a minor allele frequency
cutoﬀ of 1% and did not show deviation from Hardy-
Weinberg equilibrium at the P<10
−4 level. Rs3917564
was also found to be predictive by Carlson et al. and was
genotyped by the CVD chip but was not included in the
full analysis due to low minor allele frequency (C/T, C allele
frequency = 0.008).
The PON1 POase, DZOase, and AREase activities
were measured by a continuous spectrophotometric assay
with lithium heparin plasma, as previously described [66].
AREase activity was measured in duplicate and averaged.Journal of Lipids 3
AREase was utilized as the primary measured outcome of
PON gene cluster variation, due to its closer correlation
with protein levels. POase activity is largely determined by
the PON1Q192R missense polymorphism, which predicts over
70% of its variance [2].
2.3. Analysis. LDselect was used to create tagSNPs from
the 86 PON1, PON2, and PON3 SNPs genotyped on the
Illumina HumanCVD chip [67]. Functional annotation for
these SNPs were taken from SNP-Nexus [68]. 51 bins were
created, using a linkage disequilibrium (LD) r2 threshold of
0.64. The ﬁrst 13 of these bins, corresponding to the PON1
gene, had multiple SNPs within them, while the remaining
bins consisted of singletons. One SNP from each bin was
randomly included in the regression analysis for a total of 51
SNPsinthePON genecluster.These51SNPsdidnotinclude
thefourfunctionalSNPs,whichwereincludedintheanalysis
separately.
We also made an eﬀort to independently replicate SNPs
identiﬁed as predictive of PON1 activity by Carlson et al.
[27]. As our full sample overlaps with that smaller sample,
these were tested in a nonoverlapping sample of 523 subjects
with complete genotype and phenotype data which were not
available at the time of that study.
Regression analysis was done in R (http://www.r-project
.org/) using the standard regression tools available. Geno-
types were coded using an additive model. Stepwise linear
regression was performed, and model comparison was done
using Akaike’s Information Criterion (AIC) to examine the
ﬁt of each model, beginning with a base model that included
current smoking status, age, and the genotypes for the four
functional PON1 SNPs as covariates [2, 3, 27]. SNPs that
are included in the ﬁnal model increased the ability of the
model to predict the dependent variable. Statin drug use can
inﬂuencePON1expression,andthisappearstobeinﬂuenced
by PON1−108 genotype [69]. However, statin drug use could
not be included as a covariate due to confounding with
CAAD status; the preferential use of statins in cases can lead
toanerroneousestimation ofstatineﬀectsonPON1activity.
3. Results
The sample included 1,328 males with a mean age of 67.8
years; 16.5% of participants reported being current smokers.
The subjects included 596 cases and 644 controls considered
in the prediction of case status as well as 88 subjects with
carotid stenosis between 15–49% who were considered only
for the genotype eﬀects on PON1 activity. Cases had a mean
censored (CAAD onset) age of 66.5 years and mean current
age at enrollment age of 70.9; controls had a mean current
age of 64.6 years. The rates of current smoking and statin
use, respectively, were 25.8% and 64.7% for cases and 9.6%
and 19.5% for controls. Descriptions of the 51 tag SNPs for
the PON gene cluster are available in Table 1. The AREase
activity showed an approximately normal distribution, with
a mean of 134 U/I and standard deviation of 51.8.
A regression model containing functional PON1 SNPs
(PON1Q192R, PON1M55L, PON1−108C/T, and PON1−162A/G),
age, and current smoking status explained 25.2% of the
variance in AREase activity. To explore the possibility of
novel SNPs inﬂuencing AREase activity, we examined a
best-ﬁt model utilizing the stepwise regression including
the aforementioned variables plus the 51 tagSNPs. AIC
was used to assess whether the additional SNP provided a
better ﬁt to the prediction of AREase activity. Only SNPs
that added to the predictive power of the best-ﬁt model
were kept; others that did not inﬂuence the model were
discarded. In addition to the four functional SNPs, age,
and current smoking, six SNPs were retained in the best-
ﬁt model. Together with the original 4 functional SNPs,
these additional six SNPs in the PON gene cluster explained
30.1% of variance in AREase activity (see Table 2). Addition
of these SNPs, rs854567, rs2299257, rs2237583, rs2375005,
rs3917486, and rs11768074 serially explained an additional
2.34%, 0.85%, 0.5%, 0.34%, 0.58%, and 0.26% of total
variance in PON1 activity. Amongst these six SNPs, four
SNPs were in PON1, one was in PON2 (rs2375005), and one
was in PON3 (rs11768074); all are intronic.
Five of the six SNPs found to predict PON1 activity
were the only SNPs in their bin (singletons). The sixth SNP,
rs854567, was binned with one other typed SNP, rs2299260,
r2 = 0.80. To observe whether it was superior at predicting
PON1 AREase activity, we replaced rs854567 with rs2299260
inthecompletemodelof10SNPspluscovariates.Themodel
including rs2299260 did not predict additional AREase
activity as compared to the model including rs854567, with
a total of 30.1% of AREase variance explained in the full
model. Therefore, either SNP or an untyped SNP in LD may
be the functional SNP resulting in the association identiﬁed.
To address the potential that untyped SNPs are the
functional SNPs that underlie the identiﬁed AREase associa-
tions, the 1000 Genomes database for European ancestry was
consulted via SNP-Nexus [68] for these six SNPs. Five of the
s i xS N P sw ef o u n dt op r e d i ctP O N 1A R E a s ea ct i vi tyw e r en o t
in strong LD (r2 ≥ 0.8) with other regional SNPs, suggesting
that they may be functional. Rs2375005, in contrast, is in
strong LD with an additional ﬁve SNPs in PON3 (r2 =
0.901 with intronic rs978903 and synonymous A99A SNP
rs1053275; r2 = 0.837 with intronic rs10953146; r2 = 0.81
for intronic rs11970910 and rs117154505) [10].
Prediction of POase activity utilizing these six SNPs
that predicted AREase activity (including the base model
with age, current smoking status, and the four functional
PON1SNPs)resultedin84.02%ofPOaseenzymaticvariance
explained(seeTable 3).Thiscomparedto82.74%ofvariance
explained with the base model with the four functional
SNPs, age, and smoking status, with the high percentage
of variation explained largely due to the eﬀects of the
PONQ192R polymorphism on paraoxon catalytic eﬃciency.
Five of the six SNPs (excluding rs2237583) showed the
same directionality of their eﬀects as seen in the AREase
analysis,andthreehadsigniﬁcanteﬀectsonPOase:rs854567,
rs2299257, and rs3917486. When creating a best-ﬁt model
that allowed any of the 51 SNPs studied to enter regression
in addition to the base model, 84.96% of POase variance in
activity was explained.4 Journal of Lipids
Table 1: Characteristics of the 51 SNPs studied in the PON gene cluster.
SNP Gene Functiona Minor
alleleb
Major
allele
MAFc
rs854549 PON1 3 -downstream AC 0.337
rs3735590 PON1 3 -UTR AG 0.060
rs3917577 PON1 3 -UTR GA 0.089
rs854552 PON1 3 -UTR GA 0.265
rs3917551 PON1 Intronic AG 0.051
rs3917550 PON1 Intronic AG 0.137
rs2269829 PON1 Intronic GA 0.278
rs3917542 PON1 Intronic AG 0.227
rs3917538 PON1 Intronic AG 0.236
rs2299257 PON1 Intronic CA 0.391
rs854560 PON1 Coding TA 0.360
rs3917498 PON1 Intronic AC 0.345
rs28699500 PON1 Intronic GA 0.289
rs854561 PON1 Intronic AG 0.357
rs854565 PON1 Intronic AG 0.294
rs2272365 PON1 Intronic CA 0.154
rs854567 PON1 Intronic AG 0.185
rs3917490 PON1 Intronic AG 0.490
rs2299261 PON1 Intronic GA 0.354
rs854568 PON1 Intronic GA 0.219
rs2299262 PON1 Intronic AG 0.399
rs854569 PON1 Intronic AC 0.216
rs2237583 PON1 Intronic AG 0.284
rs3917486 PON1 Intronic AG 0.054
rs3917481 PON1 Intronic AG 0.015
rs2237584 PON1 Intronic AG 0.058
rs3917478 PON1 Intronic GA 0.118
rs3917476 PON1 Intronic AC 0.031
rs854571 PON1 5 -upstream AG 0.289
rs13236941 PON1 5 -upstream AG 0.164
rs13228784 PON1 Intronic GA 0.255
rs17883513 PON1 Intronic GA 0.032
rs17886762 PON1 Intronic AG 0.072
rs17883952 PON1 Intronic AG 0.052
rs17884000 PON3 Intronic GA 0.202
rs9640632 PON3 3 -UTR GA 0.456
rs468 PON3 Intronic GA 0.066
rs11768074 PON3 Intronic AG 0.157
rs10487132 PON3 Intronic GA 0.390
rs740264 PON3 Intronic CA 0.254
rs17884563 Intergenic Intergenic TA 0.109
rs17880030 Intergenic Intergenic AG 0.199
rs17881071 Intergenic Intergenic AG 0.198
rs2375005 PON2 Intronic TA 0.462
rs12026 PON2 Coding CG 0.240
rs2299264 PON2 Intronic AG 0.241
rs7803148 PON2 Intronic AG 0.405
rs2158806 PON2 Intronic CA 0.237
rs2286233 PON2 Intronic AT 0.131Journal of Lipids 5
Table 1: Continued.
SNP Gene Functiona Minor
alleleb
Major
allele
MAFc
rs10259688 PON2 Intronic GA 0.179
rs730365 PON2 Intronic AG 0.132
Abbreviations: UTR = untranslated region, MAF = minor allele frequency, intergenic = located between two gene regions.
a SNP functional annotation from SNP-Nexus.
b Major and minor allele annotation from the Illumina HumanCVD Bead Chip.
c Minor allele frequencies calculated from the CLEAR study cohort.
Table 2: Best-ﬁt model from stepwise linear regression predicting PON1 AREase activity.
Variable Coeﬃcient (± SE) Genea MAFb t-statisticc AREase
Variation %
P
(Intercept) 284.09 (±13.99) — — 20.304 — < 2.0 × 10−16
PON1C−108T −24.82 (±2.61) (PON1) 0.43 −9.498 14.10% < 2.0 × 10−16
PON1G−162A 4.61 (±4.60) (PON1) 0.18 1.002 0.21% 0.317
PON1Q192R −22.09 (±4.20) PON1 0.33 −5.258 1.17% 1.8 × 10−7
PON1M55L −7.05 (±3.64) PON1 0.42 −1.94 1.01% 0.053
Age −1.33 (±0.15) — — −9.014 4.29% < 2.0 × 10−16
Current smoker −28.25 (±3.63) — — −7.776 4.42% 1.95 × 10−14
rs854567 −8.19 (±4.77) (PON1) A = 0.185 −1.719 2.34% 0.086
rs2299257 12.66 (±3.57) (PON1) C = 0.391 3.546 0.85% 4.11 × 10−4
rs2237583 11.36 (±3.12) (PON1)A = 0.284 3.645 0.5% 2.82 × 10−4
rs2375005 −8.32 (±2.56) (PON2) T = 0.462 −3.25 0.34% 0.001
rs3917486 14.91 (±4.97) (PON1)A = 0.054 2.998 0.58% 0.003
rs11768074 8.42 (±4.48) (PON3)A = 0.157 1.878 0.26% 0.061
SE = standard error, MAF = minor allele frequency.
aNoncoding SNPs are presented in parentheses, for example, (PON1).
bMinorallelefrequenciesforthefourfunctionalSNPsreportedthroughdbSNP.TheremainingminorallelefrequencieswerecalculatedviatheCLEARcohort.
ct-statisticsandP valueswerecalculatedfromthecoeﬃcients(fromallsubjects)andstandarderrorswithinthebest-ﬁtmultivariatemodelbytheglmfunction
in R.
Table 3: Application of best-ﬁt model for PON1 AREase activity to predict PON1 POase activity.
Variable Coeﬃcient (± SE) Genea MAFb t-Statisticc POase
Variation %
P
(Intercept) 29.36 (±1.17) — — 24.986 — < 2.0 × 10−16
PON1C−108T −1.91 (±0.22) (PON1) 0.43 −8.762 11.78% < 2.0 × 10−16
PON1G−162A 0.78 (±0.39) (PON1) 0.18 2.023 3.93% 0.043
PON1Q192R 9.67 (±0.35) PON1 0.33 27.27 65.61% < 2.0 × 10−16
PON1M55L −1.59 (±0.30) PON1 0.42 −5.133 0.35% 3.5 × 10−7
Age −0.09 (±0.01) — — −7.475 0.78% 1.81 × 10−13
Current smoker −1.27 (±0.31) — — −4.155 0.31% 3.56 × 10−5
rs854567 −1.69 (±0.40) (PON1) A = 0.185 −4.246 0.54% 2.41 × 10−5
rs2299257 0.92 (±0.30) (PON1) C = 0.391 3.085 0.15% 0.002
rs2237583 −0.35 (±0.26) (PON1)A = 0.284 −1.347 0.09% 0.179
rs2375005 −0.23 (±0.21) (PON2) T = 0.462 −1.081 0.00% 0.28
rs3917486 2.20 (±0.42) (PON1)A = 0.054 5.271 0.47% 1.7 × 10−7
rs11768074 0.42 (±0.37) (PON3)A = 0.157 1.114 0.02% 0.266
SE = standard error, MAF = minor allele frequency.
aNon-coding SNPs are presented in parentheses, for example, (PON1).
bMinorallelefrequenciesforthefourfunctionalSNPsreportedthroughdbSNP.TheremainingminorallelefrequencieswerecalculatedviatheCLEARcohort.
ct-statisticsandP valueswerecalculatedfromthecoeﬃcients(fromallsubjects)andstandarderrorswithinthebest-ﬁtmultivariatemodelbytheglmfunction
in R.6 Journal of Lipids
Similar application to the prediction of DZOase activity
utilizing the six SNPs from the predictive AREase model
plus the base model (age, current smoking status, and
the four functional PON1 SNPs) resulted in 54.85% of
varianceexplained(seeTable 4).FiveofthesixSNPs(exclud-
ing rs11768074) showed the same directionality of their
eﬀects, and 4 had signiﬁcant eﬀects (rs2299257, rs2237583,
rs2375005, and rs3917486). When using the four functional
SNPs, age, and sex alone, 50.99% of DZOase activity was
explained. However, when allowing any of the 51 tagSNPs
to enter the best-ﬁt model, 55.60% of DZOase activity was
accounted for, suggesting that diﬀerent SNPs may aﬀect
DZOase.
We attempted to replicate SNPs previously identiﬁed by
Carlson et al. as predicting PON1 activity in a nonoverlap-
ping sample of 523 subjects (Table 5), because signiﬁcance
in an overlapping subset does not constitute replication. The
SNPs identiﬁed by Carlson et al. were rs854549, rs3917564,
rs2269829, rs854566, rs854572, and rs3917510. In our full
analysis, rs854566 was tagged by rs854567 (r2 = 0.93),
which did enter the full model using the full sample and
predicted 2.34% of AREase activity. Rs2269829 and rs854549
were not predictive of AREase in the full dataset. Rs3917564
was not included in the full model analysis due to minor
allele frequency <0.01. Rs3917510 and rs854572 (PON−909
promoter)werenottaggedintheCVDchipanalysisandwere
genotyped separately for the replication analysis. When we
considered the independent sample to test the six Carlson
SNPs in a linear model predicting AREase, which also
includedage,currentsmokingstatus,andthefourfunctional
PON1 SNPs, two of the six Carlson et al. ﬁndings were
replicated. Both rs854566 (Carlson P = 0.014, current
rs854567 P = 1.64 × 10
−5) and rs3917510 (Carlson P =
0.016, current P = 0.028) were signiﬁcant in predicting
AREase. Moreover, the direction of eﬀect for rs854566
(Carlson coeﬃcient = −10.6, current coeﬃcient = −20.4)
andrs3917510(Carlsoncoeﬃcient =16.6,currentcoeﬃcient
= 14.3) were the same in both analyses.
None of the 10 SNPs identiﬁed in our full analyses,
including the four previously known and the six newly
reported to predict AREase, predicted CAAD status, consid-
eringthecovariatescensoredageandcurrentsmokingstatus.
Moreover, none of the SNPs had a P value <0.10. However,
AREase activity, adjusted by age and current smoking status,
was highly associated with CAAD status (P = 3.62 × 10
−6),
as previously reported in a smaller sample.
4. Discussion
Only four PON1 SNPs are well established to aﬀect PON1
activity. These mutations alone account for approximately
only 25% of PON1 AREase activity, leaving a large amount
of variation left unexplained. In this study, we utilized denser
tagSNP genotyping and a 2.65-fold increased sample size
than those previously used in the Carlson et al. study [27]
to examine the eﬀects of common variants, demonstrating
the presence of additional functional genetic variance within
the PON gene cluster. We identiﬁed six additional SNPs that
predicted AREase activity (rs854567, rs2299257, rs2237583,
rs2375005, rs3917486, and rs11768074). All are intronic,
with four in PON1 and one each in PON2 (rs2375005)
and PON3 (rs11768074). Of these, only rs2375005 was
found to be in strong LD with other regional SNPs in the
1000 genomes data, which included a PON3 synonymous
SNP (rs1053275). This LD block SNP is also reported to
be in weaker LD with a PON1−1741GA promoter region
polymorphism (maximum r2 = 0.47) [34]. The remaining 5
SNPs associated with AREase may be functional or in weaker
LD with a functional site. Rs854567 alone predicted 2.3% of
the additional variance in AREase; it lies in the ﬁrst intron of
PON1, a common regulatory area.
For the many phenotypes with genetic associations to
the PON cluster, knowledge of which SNPs are associ-
ated with functional changes is helpful in determining
true associations from spurious ones. As discussed above,
rs2375005 is in strong LD with an additional ﬁve SNPs in
PON3 (rs978903, rs1053275, rs10953146, rs11970910, and
rs117154505). These include SNPs that have a reported
association with sporadic amyotrophic lateral sclerosis [10].
In addition, Riedmaier et al. have demonstrated that a
haplotype block including rs2375005 was associated with
atorvastatin lactose hydrolysis and increased PON1 mRNA
expression in liver tissue [34]. Our results validate the
presence of a functional SNP in this haplotype block.
In comparing these results to the six SNPs identiﬁed by
Carlson et al, we replicate the eﬀects of two SNPs, rs85466
and rs3917510, while failing to replicate four (Table 5)
in nonoverlapping data. Rs854566 was represented in our
analyses by the tagSNP, rs854567 (r2 = 0.93). In contrast,
the eﬀects of rs854549, rs854572, rs3917564, and rs2269829
are not replicated here. Rs854572 is 5  SNP PON1−909C/G;
while it has been associated with AREase level, smaller
studies suggested that all of its activity was attributable
to LD with the four functional SNPs [66]. The Carlson
et al. paper suggested that this site may have independent
activity, but we ﬁnd no additional eﬀects of this site, in an
independent sample of 523 subjects. In sum, our current
study conﬁrms both the eﬀects of rs854566 or its bin-mate
rs854567, predicting 2.3% of AREase activity and the eﬀects
of rs3917510, while also identifying ﬁve additional tagSNPs
that accounted for approximately 2.7% of PON1 AREase
activity that were not accounted for by Carlson et al.
The ﬁnding of PON2 and PON3 SNPs (rs2375005
and rs11768074, resp.) predicting PON1 AREase activity is
intriguing. The PON genes are in a cluster and arranged in
order from the centromere as PON1,PON3,andPON2.Each
is transcribed in the same direction, toward the centromere.
Therefore, variants in the PON2 or PON3 genes lie 5  to
PON1. Rs2375005 is in the sixth of eight PON2 introns.
Rs11768074 is in the last PON3 intron. Neither PON2 nor
PON3 has intrinsic AREase activity [70], suggesting that
these SNPs tag eﬀects on PON1. As noted above, SNPs in
the PON3 rs2375005 haplotype block have been described to
aﬀect PON1 mRNA level [34], thus the eﬀects of these SNPs,
or SNPs in LD with them, may regulate PON1 expression.
Recent research in a cohort investigating SLE has linked
rs17884563 and rs740264 in the PON3 region [53]a n dJournal of Lipids 7
Table 4: Application of best-ﬁt model for PON1 AREase activity to predict PON1 DZOase activity.
Variable Coeﬃcient (± SE) Genea MAFb t-statisticc DZOase
Activity %
P
(Intercept) 154.26 (±4.24) — — 36.365 — < 2.0 × 10−16
PON1C−108T −8.69 (±0.79) (PON1) 0.43 −11.054 12.82% < 2.0 × 10−16
PON1G−162A 5.03 (±1.40) (PON1) 0.18 3.597 5.10% 3.4 × 10−4
PON1Q192R −20.41 (±1.28) PON1 0.33 −15.944 23.71% < 2.0 × 10−16
PON1M55L −5.03 (±1.12) PON1 0.42 −4.498 3.39% 7.75 × 10−6
Age −0.44 (±0.44) — — −9.797 4.21% < 2.0 × 10−16
Current Smoker −5.65 (±1.11) — — −5.103 1.28% 4.08 × 10−7
rs854567 −2.26 (±1.44) (PON1) A = 0.185 −1.566 1.74% 0.118
rs2299257 4.03 (±1.08) (PON1) C = 0.391 3.73 0.70% 2.03 × 10−4
rs2237583 4.69 (±0.95) (PON1)A = 0.284 4.956 0.92% 8.57 × 10−7
rs2375005 −1.73 (±0.76) (PON2) T = 0.462 −2.258 0.22% 0.024
rs3917486 3.42 (±1.51) (PON1)A = 0.054 2.275 0.27% 0.023
rs11768074 −0.64 (±1.36) (PON3)A = 0.157 −0.466 0.01% 0.641
SE = standard error, MAF = minor allele frequency.
aNoncoding SNPs are presented in parentheses, for example, (PON1).
bMinorallelefrequenciesforthefourfunctionalSNPsreportedthroughdbSNP.TheremainingminorallelefrequencieswerecalculatedviatheCLEARcohort.
ct-statisticsandP valueswerecalculatedfromthecoeﬃcients(fromallsubjects)andstandarderrorswithinthebest-ﬁtmultivariatemodelbytheglmfunction
in R.
Table 5: Comparison of SNPs found signiﬁcant in prior Carlson et al.a study with current, non-overlapping sample.
SNP Seattle SNP
annotation
Carlson
coeﬃcient (±SE)
Carlson
t-Statistic b
Carlson
P c
Current
coeﬃcient
(±SE)d
Current
t-Statistic b
Current
P c
rs854566e PON16842 −10.6( ±4.3) −2.480 0.014 −20.4( ±4.68) −4.353 1.64 ×
10 −5
rs3917510 PON112471 16.6( ±6.9) 2.424 0.016 14.3( ±6.48) 2.208 0.028
rs2269829 PON119470 −16.5( ±10.8) −1.520 0.129 13.6( ±21.82) 0.625 0.533
rs3917564 PON123887 −39.0( ±18.1) −2.153 0.032 15.0( ±26.67) 0.564 0.573
rs854549 PON129021 9.2( ±4.5) 2.051 0.041 −1.3( ±4.90) −0.260 0.795
rs854572 PON1895 13.0( ±4.9) 2.677 0.008 −0.28 (±4.97) −0.056 0.955
SE = standard error.
aCarlson et al. study n = 500 European male subjects [27].
bt-Statistics and P-values were calculated from the coeﬃcients from each subgroup (Carlson n = 500, current study n = 523) and standard errors within the
best-ﬁt multivariate model by the glm function in R.
cBoth Carlson and current study utilized a linear regression model adjusting for age, current smoking status, and the four functional PON1 SNPs.
dCurrent study subset of 523 European male subjects not considered by Carlson et al.
eRepresented by proxy SNP, rs854457, with LD r2 = 0.93 in the current study.
ﬁve PON2 SNPs [52] (rs6954345, rs13306702, rs987539,
rs11982486, and rs4729189) with PON1 POase activity [52,
53]. These investigations utilized POase rather than AREase
activity [71]; this is not optimal, as the PON1Q192R activity
accounts for most POase activity. Of the PON3 SNPs found
to predict POase activity [53], both rs17884563 (intergenic
between PON2 and PON3 in our annotation) and rs740264
were directly genotyped and included in our regression
model for PON1 AREase activity but were not predictive.
When applying rs17884563 or rs740264 to POase activity,
which the aforementioned investigators used as their PON1
phenotype, neither was predictive of POase activity. For the
PON2 SNPs predictive of POase in the SLE cohort, all ﬁve
were represented by tag SNPs (r2 > 0.6), but only rs2375005
(r2 = 1 with rs987539) was predictive of PON1 AREase
activity. Interestingly, none of these ﬁve PON2 SNPs predict
POase in our data, including rs2375005 (P = 0.28). The
diﬀerences in PON2 and PON3 SNP associations between
our data and the SLE cohort may reﬂect diﬀerences in cohort
selection criteria (older male vascular disease versus younger
female SLE, cases and controls) or sizes (1,322 in our data
versus 922 in the SLE data).
Application of the six SNPs from the AREase best-ﬁt
model to predicting POase and DZOase activity resulted in
the prediction of 98.89% and 98.65% of enzymatic activity
predictedbymodels,whereall51SNPswereallowedtoenter.
Three of these six SNPs, all in PON1, also predict both PON1
POase and DZOase activities. While it is clear why coding
SNPswoulddiﬀerentiallyinﬂuencethePON1degradationof
these three substrates, it is less clear why regulatory variants8 Journal of Lipids
would. Further investigation is required to determine if and
how these noncoding SNPs diﬀerentially inﬂuence PON1’s
multipleactivitiesatthegenomic,molecular,orcellularlevel.
None of the six new SNPs that predicted AREase activity
were predictive of CAAD. In addition, none of the four
functional PON1 SNPs were predictive of CAAD, which is
consistent with past ﬁndings with smaller sample sizes in this
cohort [2, 3, 27]. Important sources of variance in AREase
activity that are not captured by these genotypes or the
covariates of age and current smoking must account for the
strong association between this activity and CAAD. Possible
sources of AREase variation include rare regional variants,
regional gene regulation not captured by genotyping (such
as methylation), variation in genes outside the PON cluster,
nongenetic factors including statin drug use [72] and diet
[73, 74], as recently reviewed [75], as well as interactions
among these. Evidence of interactions includes the report of
the association of PON1 genotype and CHD only in subjects
with diabetes [76]. These results emphasize the importance
of researching the correlation of PON1 and cardiovascular
disease more broadly by utilizing “PON status,” taking into
account both the genotype of PON1 SNPs and the plasma
activity [11, 77], as well as investigating factors which aﬀect
the speciﬁc activity of PON1. PON1 has been suggested as
a drug target for vascular and other diseases, thus a clear
understanding of its role in disease is crucial [78].
Some limitations of this study must be considered. First,
the study was comprised entirely of males of European
descent, thereby limiting the generalizations that can be
drawn from these ﬁndings. Second, this investigation con-
sidered only SNPs from the PON gene cluster. Variation in
other genes may inﬂuence PON1 activity [79]. For example,
peroxisome proliferator-activated receptor gamma (PPARG)
activates PON1 expression in hepatocytes [80], leading to
the possibility that variation in the PPARG gene could alter
levels of PON1 protein. However, the larger size of this study
and the denser tagSNPing of the PON cluster, relative to the
earlier Carlson et al. work [27] ,a l l o w e du st od e t e c tn o v e l
genetic variation that predicts PON1 AREase activity.
In conclusion, our analysis of the PON gene cluster iden-
tiﬁes six additional common genetic variants that predict
AREase activity: four are novel, predicting 2.4% of AREase
activity and two replicate past ﬁndings. The replicated SNPs
include rs854567, which tags 2.3% of AREase variance,
rs3917510, and rs2375005, which tags 0.3% of AREase vari-
ance. We do not identify additional eﬀects of the PON1−909
polymorphism. Future studies to quantify the role of rare
genetic variation and variation outside the PON cluster on
PON1 activity will be important. Finally, the continued lack
of an association between PON1, 2, or 3 genetic variants and
CAAD, while PON1 activity is highly predictive, underscores
the importance of utilizing PON status in future studies
investigating the link between PON1 and vascular or other
disease.
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